These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 27038373)

  • 1. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.
    Cui M; Gosu V; Basith S; Hong S; Choi S
    Adv Protein Chem Struct Biol; 2016; 104():81-125. PubMed ID: 27038373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capsaicin receptor: TRPV1 a promiscuous TRP channel.
    Pingle SC; Matta JA; Ahern GP
    Handb Exp Pharmacol; 2007; (179):155-71. PubMed ID: 17217056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Capsaicin, Nociception and Pain.
    Frias B; Merighi A
    Molecules; 2016 Jun; 21(6):. PubMed ID: 27322240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRPV1 signaling: mechanistic understanding and therapeutic potential.
    Xia R; Samad TA; Btesh J; Jiang LH; Kays I; Stjernborg L; Dekker N
    Curr Top Med Chem; 2011; 11(17):2180-91. PubMed ID: 21671876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRPV1 antagonists: the challenges for therapeutic targeting.
    Khairatkar-Joshi N; Szallasi A
    Trends Mol Med; 2009 Jan; 15(1):14-22. PubMed ID: 19097938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescence-Based Assay for TRPV1 Channels.
    Moriello AS; De Petrocellis L; Vitale RM
    Methods Mol Biol; 2023; 2576():119-131. PubMed ID: 36152181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel.
    Nagy I; Friston D; Valente JS; Torres Perez JV; Andreou AP
    Prog Drug Res; 2014; 68():39-76. PubMed ID: 24941664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
    Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
    J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the transient receptor potential vanilloid-1 (TRPV1) channel opens the gate for pain relief.
    Jancsó G; Dux M; Oszlács O; Sántha P
    Br J Pharmacol; 2008 Dec; 155(8):1139-41. PubMed ID: 18997813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
    García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
    J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
    Knotkova H; Pappagallo M; Szallasi A
    Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TRPV1 antagonists as a potential treatment for hyperalgesia.
    Roberts LA; Connor M
    Recent Pat CNS Drug Discov; 2006 Jan; 1(1):65-76. PubMed ID: 18221192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient receptor potential vanilloid 1 as a therapeutic target in analgesia.
    Szolcsányi J; Pintér E
    Expert Opin Ther Targets; 2013 Jun; 17(6):641-57. PubMed ID: 23421411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond Hot and Spicy: TRPV Channels and their Pharmacological Modulation.
    Seebohm G; Schreiber JA
    Cell Physiol Biochem; 2021 May; 55(S3):108-130. PubMed ID: 34043299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Driven Pharmacology of Transient Receptor Potential Channel Vanilloid 1.
    Díaz-Franulic I; Caceres-Molina J; Sepulveda RV; Gonzalez-Nilo F; Latorre R
    Mol Pharmacol; 2016 Sep; 90(3):300-8. PubMed ID: 27335334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.
    Szallasi A; Cortright DN; Blum CA; Eid SR
    Nat Rev Drug Discov; 2007 May; 6(5):357-72. PubMed ID: 17464295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multisteric TRPV1 nocisensor: a target for analgesics.
    Szolcsányi J; Sándor Z
    Trends Pharmacol Sci; 2012 Dec; 33(12):646-55. PubMed ID: 23068431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
    Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
    J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the transient receptor potential vanilloid type 1 (TRPV1) assembly domain attenuates inflammation-induced hypersensitivity.
    Flynn R; Chapman K; Iftinca M; Aboushousha R; Varela D; Altier C
    J Biol Chem; 2014 Jun; 289(24):16675-87. PubMed ID: 24808184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chalcone derivatives as non-canonical ligands of TRPV1.
    Benso B; Bustos D; Zarraga MO; Gonzalez W; Caballero J; Brauchi S
    Int J Biochem Cell Biol; 2019 Jul; 112():18-23. PubMed ID: 31026506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.